What has been really said in the last meeting...Again from transcript... https://finance.yahoo.com/news/edited-transcript-th-earnings-conference-150738988.html?.tsrc=rss
...From the short-term perspective, the sales run rate of Trogarzo should surpass that of EGRIFTA by the end of the first year of commercialization, which is in line with I have been saying ever since we obtained commercial rights to the product, but this is now supported by what we have been witnessing, thus far, with Trogarzo.
Looking at the longer term, Trogarzo peak sales could be 5x or more than those of EGRIFTA, so we believe that such objectives are both achievable and realistic. Some may have thought that because Trogarzo is an exceptional lifesaving treatment that sales will reach their peak overnight. Of course, this is not in line with what I always tell to the investment community. It takes time for a new drug to gain momentum, and Trogarzo is no exception.
Building the market for a niche injectable product takes more than a few months. Many ingredients need to come together before sales can gather that momentum. This is what we have been focusing on for the last several month...